Sequantrix

Executive Summary

Sequantrix is a Munich-based pre-clinical biotech founded in 2020, leveraging AI and machine learning to discover novel therapies for kidney disease, heart failure, and hematology. The company was founded by leading researchers in these fields and computational scientists, aiming to address high unmet medical needs. With no disclosed funding or valuation, Sequantrix operates in stealth mode, focusing on preclinical validation of its AI-driven drug discovery platform. The convergence of AI and biology positions it to potentially accelerate the identification of therapeutic targets and biomarkers, though the early stage and lack of public pipeline data imply high risk. The company's success hinges on advancing its programs into clinical development and securing strategic partnerships.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Round50% success
• H1 2027Lead Program IND Submission30% success
• Q2 2027Pharma Collaboration Announcement40% success